EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mesenchymal stromal cells conditioned by peripheral blood mononuclear cells exert enhanced immunomodulation capacities and alleviate a model of Myasthenia Gravis

Alexandra C Bayer, Natalia Pinzón, Axel You, Cinthia Bergman, Nadine Dragin, Aurélien Corneau, Frédérique Truffault, Danièle Noël, Christophe Martinaud, Rozen Le Panse, Sonia Berrih-Aknin, Jean-Thomas Vilquin

Stem Cell Research & Therapy · 08.08.2025 · 16 (1)

DOI: 10.1186/s13287-025-04534-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stem Cell Research & Therapy, online erschienen am 08.08.2025. Verfasst von Alexandra C Bayer und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, INSERM, Institut de Myologie, GH Pitié-Salpêtrière, Centre de Recherche en Myologie, Paris, F-75013, France. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Leukocytes, Mononuclear, Immunomodulation, Myasthenia Gravis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, Institut de Myologie, Sorbonne Université.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mesenchymal Stromal Cells (MSC) possess innate immunomodulatory properties, which can be significantly enhanced through co-culture with peripheral blood mononuclear cells (PBMC), making them attractive tools for the treatment of autoimmune and inflammatory diseases.

Methods

Leveraging a multi-omics approach encompassing RNA sequencing, flow and mass cytometry, secretome analysis, completed by functional evaluations, we investigated the mechanisms underpinning PBMC conditioning of MSC in vitro and their benefits in an animal model of Myasthenia gravis. MSC derived from human adipose tissue were left untreated in resting state (rMSC), conditioned by PBMC (cMSC), or activated by the pro-inflammatory molecule interferon (IFN)-γ (γMSC), then compared for their gene expression profiles, phenotypes and functional capacities.

Results

RNA sequencing identified 244 differentially expressed genes in cMSC compared to rMSC, highlighting key immune mediators such as CCL2 , CCL11 , DPP4 , ICAM1 , IL6 , PDCD1LG2 , TNFRSF11B , TNIP1 , TNIP3 and ZC3H12A and pinpointing genes involved in matrix remodeling, paracrine and autocrine communications. Comparatively, 2089 genes were differentially expressed between rMSC and γMSC, highlighting host defense, anti-viral response, NFκB signaling pathways modulated by IFN-γ. Flow and mass cytometry analyses revealed upregulation of the surface markers CD26, CD54, and CD273 and intracellular molecules IDO1 and PTGS2 in cMSC. In contrast, IFN-γ activation predominantly increased HLA-related markers while also enhancing the homogeneity of the populations. Together, these results underlined the treatment dependence of transcriptomic and phenotypic signatures. Secretome profiling identified 6 categories of modulated proteins, out of which 22 molecules potentially involved in PBMC conditioning and 40 implicated in cMSC-mediated immunomodulation. Functionally, cMSC induced modulation in PBMC subsets, raising the proportions of lymphocyte populations (CD4 Treg, CD8, B memory), underlining the multimodal effect of conditioning. Also, both a direct cell-cell contact and cMSC supernatants significantly suppressed activated T-cell proliferation in vitro. To confirm immunomodulation efficacy in vivo, cMSC were administrated to our humanized mouse model of Myasthenia Gravis and the treatment significantly halved disease severity from 2 weeks post-injection.

Conclusions

This integrative study establishes distinct conditioning signatures, suggests molecular mechanisms, and underscores the therapeutic potential of cMSC, offering a robust framework for advancing cell-based therapies in autoimmune diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem CellsLeukocytes, MononuclearImmunomodulationMyasthenia GravisHumansAnimalsMiceFemaleInterferon-gammaDisease Models, AnimalCoculture Techniques

Stichwörter der Autor:innen

ConditioningHumanized mouse modelImmunomodulationInhibition of proliferationMass cytometryMesenchymal stromal cellsMyasthenia gravisRNASeqSecretomeγ-Interferon

Substanzen

Interferon-gamma

Autor:innen und Institutionen

  • Sorbonne Université, INSERM, Institut de Myologie, GH Pitié-Salpêtrière, Centre de Recherche en Myologie, Paris, F-75013, France.
  • Department of Neurology and Immunobiology, Yale University School of Medicine, New Haven, CT, 06520, USA.
  • Institut de Myologie, plateforme MyoData, Paris, F-75013, France.
  • Sorbonne Université, Plateforme de Cytométrie de la Pitié-Salpêtrière (CyPS), Paris, F-75013, France.
  • IRMB, Université de Montpellier, INSERM, Montpellier, F-34295, France.
  • INSERM, Unité des Médicaments de Thérapie Innovante, Centre de Transfusion Sanguine des Armées, Clamart, F-92140, France.

Förderung

  • Agence Nationale de la Recherche
  • Institut de Myologie
  • Sorbonne Université
  • Inserm
  • Centre National de la Recherche Scientifique

Zitieren

APA

Bayer, A. C., Pinzón, N., You, A., Bergman, C., Dragin, N., Corneau, A., Truffault, F., Noël, D., Martinaud, C., Le Panse, R., Berrih-Aknin, S., & Vilquin, J. T. (2025). Mesenchymal stromal cells conditioned by peripheral blood mononuclear cells exert enhanced immunomodulation capacities and alleviate a model of Myasthenia Gravis. Stem Cell Research & Therapy, 16(1). https://doi.org/10.1186/s13287-025-04534-9

Vancouver

Bayer AC, Pinzón N, You A, Bergman C, Dragin N, Corneau A, et al. Mesenchymal stromal cells conditioned by peripheral blood mononuclear cells exert enhanced immunomodulation capacities and alleviate a model of Myasthenia Gravis. Stem Cell Research & Therapy. 2025;16(1). doi:10.1186/s13287-025-04534-9

BibTeX
@article{Bayer2025,
  author = {Bayer, Alexandra C and Pinzón, Natalia and You, Axel and Bergman, Cinthia and Dragin, Nadine and Corneau, Aurélien and Truffault, Frédérique and Noël, Danièle and Martinaud, Christophe and Le Panse, Rozen and Berrih-Aknin, Sonia and Vilquin, Jean-Thomas},
  title = {Mesenchymal stromal cells conditioned by peripheral blood mononuclear cells exert enhanced immunomodulation capacities and alleviate a model of Myasthenia Gravis},
  journal = {Stem Cell Research & Therapy},
  year = {2025},
  volume = {16},
  number = {1},
  doi = {10.1186/s13287-025-04534-9}
}
Kostenlos starten →